PYC Therapeutics Ltd
ASX:PYC ISIN:AU000000PYC7
PYC Therapeutics Ltd (ASX:PYC) is a pre-clinical stage biotechnology company pioneering a new generation of RNA therapeutics that utilise PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines.
View in Other Languages
News
Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.
Australian Market Report of December 20, 2010 includes: IMX Resources Limited (ASX:IXR) has sailed its first shipment of iron-copper ore to China; Phylogica Limited (ASX:PYC) signed collaboration and licensing deal with Pfizer (NYSE:PFE); Copper Strike Limited (ASX:CSE) received strong copper/silver/cobalt results at Walford Creek in Northwest Queensland; South American Ferro Metals Limited (ASX:SFZ) iron ore production in Brazil exceeds 400,000 tonnes.
The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.
PHYLOGICA LIMITED (ASX: PYC) - Market Briefing - Dr Stewart Washer, CEO; Boardroomradio is pleased to announce that PHYLOGICA LIMITED (ASX: PYC) has published an audio file. The following presentation
###
82,610 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 29) (Last 30 Days: 109) (Since Published: 10664)
